Overview

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with tenofovir and emtricitabine or tenofovir and emtricitabine combined with zidovudine and abacavir, as assessed by change from baseline plasma HIV-1 RNA viral load.
Phase:
Phase 4
Details
Lead Sponsor:
Kirby Institute
Collaborator:
The University of New South Wales
Treatments:
Abacavir
Atazanavir Sulfate
Efavirenz
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Ritonavir
Tenofovir
Zidovudine